about
Haloperidol discontinuation for schizophreniaHaloperidol dose for the acute phase of schizophreniaHaloperidol versus placebo for schizophreniaHaloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)Antipsychotic medication for early episode schizophreniaAripiprazole versus typical antipsychotic drugs for schizophreniaTestosterone for schizophreniaRisperidone versus olanzapine for schizophreniaAripiprazole for schizophreniaTrifluoperazine for schizophreniaNew generation antipsychotics for first episode schizophreniaPharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for cliniciansCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatmentBehavioural and functional characterization of Kv10.1 (Eag1) knockout miceA Bayesian framework to account for uncertainty due to missing binary outcome data in pairwise meta-analysis.Imputation methods for missing outcome data in meta-analysis of clinical trialsPackages of care for schizophrenia in low- and middle-income countries.If you could only choose five psychotropic medicines: updating the interagency emergency health kit.Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.Exploring schizophrenia drug-gene interactions through molecular network and pathway modelingA single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophreniaGene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.Are second generation antipsychotics a distinct class?Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervalsUsing the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs.Where Does Evidence from New Trials for Schizophrenia Fit with the Existing Evidence: A Case of the Emperor's New Clothes?A commentary on "Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders".Glossopharyngeal Dystonia Secondary to a Lurasidone-Fluoxetine CYP-3A4 InteractionAntidepressant and Antipsychotic Drugs.Neuroprotective effects of alpha lipoic Acid on haloperidol-induced oxidative stress in the rat brainHaloperidol versus chlorpromazine for treatment of schizophrenia.Functional Changes of Orexinergic Reaction to Psychoactive Substances.Risperidone versus placebo for schizophrenia
P2860
Q24187607-E9AFD258-A6B3-4DC0-95A8-D540D77A6A4DQ24200200-9ABC49B6-45A9-4E94-B259-321A57141ABCQ24202457-D1B94A11-AE9E-47B5-9955-56F918B5FC31Q24203034-F06EF8B2-5C88-45D5-A862-0D8806518E9AQ24236683-222F4036-4172-4690-9D53-EABCEE8F2533Q24241974-B6C772A7-6DE3-4717-8202-89CCB7C1C86DQ24243894-7B1FFD38-7951-4921-8421-F7BD689C2F74Q24246232-57663F18-0CCC-4A14-93CD-65B9423C20F3Q24246298-5689F97A-AEFD-4CB4-8A5F-7A3FF3BAE0A5Q24247440-ECDC26DB-D549-4420-B33E-11971AB9C14BQ24247720-C37049E0-F607-4A93-8516-2E5E0D20CA18Q24657338-8BAC6840-5B28-4007-A7DD-AE9D45CD6E9EQ27003099-C0390D4B-4F5D-4657-909F-C10DB561DD46Q28972478-4A5748A7-CE3A-41DE-8193-6A7D586587B1Q30454673-92BD3CFC-92BD-4AF6-8069-DC70D5CE9082Q30916412-67BA32D4-5916-402B-92A5-D34DCA18028AQ31159481-DC8F4AF0-05DA-4FD5-AF71-1F65B262703DQ33511434-3063BBF6-D9E9-4630-A350-0DEFE1B2B45AQ33894795-E7E8F83D-AB8C-45A5-B1C9-9977E58E2C36Q35061441-41B5CD00-3E67-4E11-B10A-33A74B364E37Q35624956-FD34B9ED-529D-4615-995E-E4D9C8D33241Q35732320-6F6BBFA5-46CB-43A4-B7B2-9F383DE512B0Q36754038-1D8F1223-EAA5-4260-8650-8734D4964E49Q36784527-4A957030-D291-4D29-972F-8E688198BE31Q37371191-A0D8F9B6-69BA-45E2-BFDA-CF6CAA53DAD9Q37937746-26992BA5-1E03-4B7E-849F-BE199C9FB44EQ39555105-0007A408-21C8-4929-9708-4B856BC86866Q41117908-1FC4EA08-781D-44B2-BDB0-935D114E1D99Q41429342-6FF266D8-75FB-4E6D-A920-25323632BAF3Q42018725-44490817-3C9C-408F-B147-1007C00DD39AQ42100689-C21F5859-E73A-4695-8ED3-7BE22D61CCDDQ43192045-5339E76B-5E6B-41FB-810E-2878A67F9AD0Q47201475-2E501DF5-B1CE-4810-969E-01EEB231BF80Q55894951-9875539A-F6A4-4967-817B-474AA91AA71B
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Haloperidol versus placebo for schizophrenia
@ast
Haloperidol versus placebo for schizophrenia
@en
Haloperidol versus placebo for schizophrenia
@en-gb
Haloperidol versus placebo for schizophrenia
@nl
type
label
Haloperidol versus placebo for schizophrenia
@ast
Haloperidol versus placebo for schizophrenia
@en
Haloperidol versus placebo for schizophrenia
@en-gb
Haloperidol versus placebo for schizophrenia
@nl
prefLabel
Haloperidol versus placebo for schizophrenia
@ast
Haloperidol versus placebo for schizophrenia
@en
Haloperidol versus placebo for schizophrenia
@en-gb
Haloperidol versus placebo for schizophrenia
@nl
P2860
P1476
Haloperidol versus placebo for schizophrenia
@en
P2093
Claire B Irving
P2860
P356
10.1002/14651858.CD003082.PUB2
P407
P577
2006-10-18T00:00:00Z